You just read:

Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo

News provided by

Eli Lilly and Company

Feb 15, 2017, 16:56 ET